Thermo Fisher Scientific Launches First Clinical Next-Generation Sequencing Oncology Quality Control

CARLSBAD, Calif.--(BUSINESS WIRE)--Clinical laboratories running next-generation sequencing (NGS) oncology tests now have access to a universal quality control material compatible with multiple sequencing platforms. The AcroMetrix Oncology Hotspot Control provides a common quality control material that can be used across laboratories with different NGS instrument platforms, assays and bioinformatics pipelines to test precision and detect analytical deviations that may arise from reagent and instrument variation.

The Oncology Hotspot Control allows users to control for more than 500 hotspot mutations with a single QC control and contains cancer-associated mutations across 53 genes, including KRAS, BRAF, ERBB2, EGFR and TP53. Users can choose from 500 single nucleotide variants, 19 insertions, 29 deletions, and three complex mutations.

Hey, check out all the engineering jobs. Post your resume today!